NCT00425321 - Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy | Biotech Hunter

Enrollment

259

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Rheumatoid Arthritis

Interventions

DRUG

RWJ-445380 100 mg

RWJ-445380 100 mg once daily for up to 12 weeks

DRUG

RWJ-445380 200 mg

RWJ-445380 200 mg once daily for up to 12 weeks

DRUG

RWJ-445380 300 mg

RWJ-445380 300 mg once daily for up to 12 weeks

DRUG

Placebo

Placebo once daily for up to 12 weeks

Trial Locations (42)

Unknown

Birmingham

Huntsville

Tucson

Fair Oaks

Whittier

Waterbury

Sarasota

Morton Grove

Springfield

Frederick

Duncansville

Nashville

Austin

Buenos Aires

Federal

Luján

Curitiba

Porto Alegre

São Paulo

Brno

Plzeò 1

Prague

Uherské Hradiště

Zlín

Bad Abbach

Bad Nauheim

Dresden

Essen

Frankfurt

Herne

Leipzig

Guadalajara

Mexico City

México

San Luis Potosí City

Bialystok

Bydgoszcz

Krakow

Lublin

Poznan

Szczecin

Warsaw

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY